Digital Pharmaceutical Process Design: Faster, Cost Effective and Sustainable Delivery of Quality Drug Substance
Through digital-first process design, CMAC researchers decrease the material required for API development by an order of magnitude.
From Lab to Clinical Development: CMAC’s Impurity Rejection Workflow
Researchers at Eli Lilly & Company have successfully applied CMAC’s impurity rejection workflow in clinical development, achieving up to 100% rejection of problematic impurities.